Weight Loss Comparison: Empagliflozin vs Dapagliflozin
Both empagliflozin and dapagliflozin produce similar weight loss effects in adults with type 2 diabetes, with no clinically meaningful difference between the two agents. The choice between them should be based on cardiovascular and renal outcomes rather than weight loss potential.
Evidence on Weight Loss Effects
Class Effect on Weight Loss
SGLT2 inhibitors as a class produce modest but consistent weight reduction through increased urinary glucose excretion (approximately 60-80 grams of glucose daily). A 2015 Endocrine Society guideline meta-analysis found that SGLT2 inhibitors led to a mean weight loss of -2.37% of initial body weight compared to placebo 1.
The weight loss appears to be a class effect with minimal differences between individual agents. The same analysis showed:
- Dapagliflozin: -2.06% mean weight loss (95% CI: -2.73 to -1.74)
- Canagliflozin: -2.61% mean weight loss (95% CI: -3.09 to -2.13)
While canagliflozin showed numerically greater weight loss, this difference was not statistically significant 1.
Dose-Response Relationship
A 2018 meta-analysis of 55 placebo-controlled trials demonstrated a dose-dependent weight reduction with dapagliflozin 2:
- 2.5 mg: -1.30 kg
- 5 mg: -1.51 kg
- 10 mg: -1.79 kg
- 20 mg: -2.24 kg
Similar dose-dependent effects were observed with canagliflozin (50-300 mg) and empagliflozin 2.
Direct Comparison Data
The most recent 2025 guideline on glycemic management notes that empagliflozin (10-25 mg) produces HbA1c reductions of 0.48-0.84%, while dapagliflozin (5-10 mg) produces reductions of 0.5-0.7% 3. However, this guideline does not identify clinically significant differences in weight loss between these two specific agents.
Real-world data from a 2020 study comparing empagliflozin and dapagliflozin in 119 patients found both agents produced significant weight and BMI reductions at 6 months, though the study did not report between-group comparisons for weight loss specifically 4.
Clinical Context
When Weight Loss is the Primary Goal
If weight loss is your primary therapeutic objective in a patient with type 2 diabetes:
- GLP-1 receptor agonists are superior to SGLT2 inhibitors for weight reduction, producing losses of -0.6 to -1.8 kg compared to SGLT2 inhibitors' -2.37% of body weight 1
- The 2025 BMJ guideline specifically recommends GLP-1 receptor agonists over SGLT2 inhibitors when obesity is present and weight reduction is prioritized 5
Choosing Between Empagliflozin and Dapagliflozin
Since weight loss effects are equivalent, base your decision on:
- Cardiovascular disease: Both agents reduce cardiovascular death and heart failure hospitalization in patients with established CVD 6
- Heart failure: Both dapagliflozin (DAPA-HF) and empagliflozin (EMPEROR-Reduced, EMPEROR-Preserved) reduce heart failure outcomes regardless of diabetes status 7, 8
- Chronic kidney disease: Dapagliflozin has specific FDA approval and guideline support for CKD with or without diabetes (DAPA-CKD trial) 9, 7
Important Caveats
- Weight loss with SGLT2 inhibitors plateaus at approximately 24 weeks with no weight regain through 52 weeks 1
- The weight reduction is modest (typically 2-3 kg) and should not be the sole reason for choosing an SGLT2 inhibitor
- Both agents require adequate renal function (eGFR ≥25 mL/min/1.73 m²) for cardiovascular benefits, though glycemic efficacy diminishes below eGFR 45 mL/min/1.73 m² 10
- Genital mycotic infections occur in both agents (moderate certainty evidence) 5
Bottom line: Choose empagliflozin or dapagliflozin based on your patient's cardiovascular and renal profile, not weight loss potential, as both produce equivalent modest weight reduction.